IMMUCOR INC
4, 1996-06-10
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: IDENTIX INC, 8-K/A, 1996-06-10
Next: SGI INTERNATIONAL, ARS, 1996-06-10



                 U.S. SECURITIES AND EXCHANGE COMMISSION
                        Washington, D.C. 20549

                                 FORM 4

               Statement of Changes in Beneficial Ownership

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, 
Section 17(a) of the Public Utility Holding company Act of 1935 or 
Section 30(f) of the Investment Company Act of 1940

____	Check this box if no longer subject to Section 16.  Form 4 or Form 5 
obligations may continue.  See Instruction 1(b).


1.	Name and Address of Reporting Person

  	Wilms, Josef
  	Immucor GmbH
   Post Box 20 02 47
  	Adam-Opel-Str. 26, Germany

2.	Issuer Name and Ticker or Trading Symbol

  	Immucor, Inc./BLUD

3.	IRS or Social Security Number of Reporting Person (Voluntary)

  	Not Applicable

4.	Statement for Month/Year

  	5/96

5.	If Amendment, Date of Original (Month/Year)

  	Not Applicable

6.	Relationship of Reporting Person to Issuer (check all applicable)

  	X	Director
		   Officer (give title below)
		   10% Owner
   		Other (specify below)

		Managing Director - Immucor GmbH

TABLE I - Non-Derivative Securities Acquired, Disposed of, or Beneficially 
          Owned

1.	Title of Security (Instr. 3)

   Not applicable

2.	Transaction Date (Month/Day/Year)
	
   Not applicable

3.	Transaction Code (Instr. 8)

	   Code		           V
	   Not applicable

4.	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)

  	Amount	       (A) or (D)	          Price

   Not applicable				

5.	Amount of Securities     	6.	Ownership Form:	        7.	Nature of Indirect
 	Beneficially Owned at 		   Direct (D) or Indirect (I)		  Beneficial Ownership
	 End of Month (Instr. 3		        (Instr. 4)		                (Instr. 4)
	 and 4)
			
  Not applicable	


TABLE II - Derivative Securities Acquired, Disposed of, or Beneficially 
Owned (e.g., puts, calls, warrants, options, convertible securities)

1.	Title of Derivative Security (Instr. 3)

a)  Common Stock Warrant - Right to Buy
b)  Common Stock Warrant - Right to Buy
c)  Common Stock Warrant - Right to Buy
d)  Common Stock Warrant - Right to Buy


2.	Conversion or Exercise Price of Derivative Security

a)  $7.75/share
b)  $7.75/share
c)  $7.75/share
d)  $7.75/share

3.	Transaction Date (Month/Day/Year)

a)  5/21/96
b)  5/22/96
c)  5/23/96
d)  5/24/96

4.	Transaction Code (Instr. 8)

	Code		              	V
a)  X		         Not applicable
b)  X		         Not applicable
c)  X		         Not applicable
d)  X		         Not applicable

5.	Number of Derivative Securities Acquired (A) or Disposed of (D) 
(Instr. 3, 4 and 5)
 
	       (A)				                     (D)
a)  Not applicable               	18,300
b)  Not applicable		               8,200
c)  Not applicable		              11,200
d)  Not applicable		              12,300 

6.	Date Exercisable and Expiration Date (Month/Day/Year)

Date Exercisable  		Expiration Date
a)  9/28/91			         9/28/00
b)  9/28/91			         9/28/00
c)  9/28/91			         9/28/00
d)  9/28/91			         9/28/00

7.	Title and Amount of Underlying Securities (Instr. 3 and 4)

          	Title						            Amount or Number of Shares
a)  Common Stock, $.10 par value	          	18,300
b)  Common Stock, $.10 par value		           8,200
c)  Common Stock, $.10 par value		          11,200
d)  Common Stock, $.10 par value		          12,300
			

8.	Price of Derivative Security (Instr. 5)

	Not applicable


9.	Number of Derivative Securities Beneficially Owned at End of Month (Instr. 4)

	Other options previously reported = 293,000

10.	Ownership Form of Derivative Security:  Direct (D) or Indirect (I) 
(Instr. 4)

	D

11.	Nature of Indirect Beneficial Ownership (Instr. 4)

	Not applicable

Explanation of Responses:

	Not applicable



/s/ Josef Wilms
Signature of Reporting Person

6/10/96
Date




© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission